TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares stood at 0.51 million during the latest session, with the company’s beta value hitting 2.30. At the last check today, the stock’s price was $17.24, to imply an increase of 0.70% or $0.12 in intraday trading. The TGTX share’s 52-week high remains $35.22, putting it -104.29% down since that peak but still an impressive 62.53% since price per share fell to its 52-week low of $6.46. The company has a valuation of $2.66B, with an average of 3.79 million shares over the past 3 months.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
After registering a 0.70% upside in the latest session, TG Therapeutics Inc (TGTX) has traded red over the past five days. The stock hit a weekly high of 17.63, jumping 0.70% in its intraday price action. The 5-day price performance for the stock is 4.99%, and 17.20% over 30 days. With these gigs, the year-to-date price performance is 0.94%.
TG Therapeutics Inc (TGTX) estimates and forecasts
Looking at statistics comparing TG Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. TG Therapeutics Inc (TGTX) shares are 59.19% up over the last 6 months, with its year-to-date growth rate lower than industry average at -111.11% against 18.10%. The rating firms project that company’s revenue will grow 32.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 65.89M. Meanwhile, for the current quarter, a total of 7 analyst(s) estimate revenue growth to 77.98M.Earnings reports from the last fiscal year show that sales brought in 17.45M and 46.56M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 277.60% before jumping 67.50% in the following quarter.
TGTX Dividends
TG Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. TG Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
